Mdm2 Deficiency Suppresses MYCN-Driven Neuroblastoma Tumorigenesis In Vivo  by Chen, Zaowen et al.
Mdm2 Deficiency Suppresses
MYCN-Driven Neuroblastoma
Tumorigenesis In Vivo1
Zaowen Chen*,2, Yunfu Lin†,2, Eveline Barbieri*,
Sue Burlingame*, John Hicks‡, Andrew Ludwig*
and Jason M. Shohet*
*Texas Children’s Cancer Center and Center for Cell
and Gene Therapy, Baylor College of Medicine, Houston,
TX 77030, USA; †Department of Biochemistry and
Molecular Biology, Baylor College of Medicine, Houston,
TX 77030, USA; ‡Department of Pathology, Baylor College
of Medicine, Houston, TX 77030, USA
Abstract
Neuroblastoma is derived from neural crest precursor components of the peripheral sympathetic nervous system
and accounts for more than 15% of all pediatric cancer deaths. A clearer understanding of the molecular basis of
neuroblastoma is required for novel therapeutic approaches to improve morbidity and mortality. Neuroblastoma is
uniformly p53 wild type at diagnosis and must overcome p53-mediated tumor suppression during pathogenesis.
Amplification of theMYCN oncogene correlates with the most clinically aggressive form of the cancer, and MDM2,
a primary inhibitor of the p53 tumor suppressor, is a direct transcriptional target of, and positively regulated by,
both MYCN and MYCC. We hypothesize that MDM2 contributes to MYCN-driven tumorigenesis helping to ame-
liorate p53-dependent apoptotic oncogenic stress during tumor initiation and progression. To study the interaction
of MYCN and MDM2, we generated an Mdm2 haploinsufficient transgenic animal model of neuroblastoma. In
Mdm2+/− MYCN transgenics, tumor latency and animal survival are remarkably extended, whereas tumor inci-
dence and growth are reduced. Analysis of the Mdm2/p53 pathway reveals remarkable p53 stabilization counter-
balanced by epigenetic silencing of the p19Arf gene in the Mdm2 haploinsufficient tumors. In human
neuroblastoma xenograft models, conditional small interfering RNA–mediated knockdown of MDM2 in cells ex-
pressing wild-type p53 dramatically suppresses tumor growth in a p53-dependent manner. In summary, we pro-
vided evidence for a crucial role for direct inhibition of p53 by MDM2 and suppression of the p19ARF/p53 axis in
neuroblastoma tumorigenesis, supporting the development of therapies targeting these pathways.
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Introduction
Neuroblastoma is an aggressive neural crest–derived pediatric malig-
nancy for which there has been little improvement in outcomes for
the past decade. With less than 40% long-term survival for metastatic
disease, it accounts for at least 15% of all pediatric cancer deaths
despite intense treatment regimens combining high-dose chemother-
apy, surgery, and radiation [1]. Improving neuroblastoma therapy
will require an improved understanding of the molecular pathogen-
esis and pathophysiology of disease development and progression.
Whereas the MYCN (N-Myc) oncogene has long been associated with
malignant transformation in neuroblastoma [2], recent work demon-
strates an important pathogenic role for MYCC (C-Myc) as well [3].
The p53 apoptotic mechanisms are intact in MYCN-positive neuro-
blastomas [4], and MDM2 inhibition leads to an immediate onset of
apoptosis [5,6].
A crucial observation for neuroblastoma is that less than 2% of
de novo cancers have mutated p53 [7,8], and its downstream effector
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pathways leading to cell cycle arrest and apoptosis are functionally
active in most neuroblastoma tumors and cell lines [4,9–11]. This
suggests that inhibition of p53 activation upstream plays a critical
role in neuroblastoma tumorigenesis and that therapeutic reversal
of this inhibition should, in principle, lead to p53 activation and
tumor death in vivo [6,12]. Several in vitro and in vivo studies of
MYCN demonstrate that this oncogene promotes cellular prolifera-
tion, metastasis, and genomic instability while also activating p53-
mediated apoptotic stress responses [13]. A deeper understanding
of the mechanisms regulating the balance between proliferation and
apoptosis in MYC oncogene stressed that cells will aid the rational
design of better-targeted molecular therapies.
MYCN gene amplification remains the strongest negative prognos-
tic marker in neuroblastoma conferring a particularly poor term sur-
vival [14–16]. MYCN is amplified (>10 copies per cell) in more than
25% of neuroblastomas and is associated with an extremely aggres-
sive metastatic phenotype. Interestingly, in MYCN nonamplified tu-
mors, the levels of MYCN transcript and MYCN protein do not
correlate as well with outcome [16–18]. It is also now apparent that
the MYCC gene is frequently overexpressed in cells with low MYCN
levels, suggesting that a common MYC-dependent transcriptional pro-
file contributes to the pathogenesis of this type of cancer [3]. Several
studies demonstrate that Myc oncogenes activate and repress a large
number of genes directly through protein/DNA interactions [19] and
through deregulation of microRNA [20–22]. Yet, how MYCN and
MYCC specifically act to overcome p53-dependent cell cycle regula-
tion and apoptosis in neuroblastoma remains to be elucidated.
The neuroblastoma-specific tumorigenic influence of MYCN was
confirmed in a transgenic mouse model that targets the expression of
human MYCN to neural crest cells using the tyrosine hydroxylase
promoter (pTH-MYCN) [23]. These mice develop neuroblastoma
that is histologically and genetically very similar to aggressive undiffer-
entiated human neuroblastoma [24]. Importantly, the mouse model
of neuroblastoma faithfully recapitulates the p53 wild-type status,
chemosensitivity, and p53-dependent apoptotic responses of human
neuroblastoma [25,26]. We modified this model to assess how MDM2
haploinsufficiency alters MYCN-driven tumorigenesis.
Amplification of the MDM2 gene occurs in approximately 10%
of human tumors (>30% of primarily sarcomas) and 2% of neu-
roblastoma, usually without coincident p53 mutation [11,27,28].
Transgenic mice overexpressing Mdm2 develop a wide spectrum of
cancer suggesting that high MDM2 levels can overcome p53 tumor
suppressor activity [29]. In line with these observations, inhibition of
MDM2 with a small molecule that blocks the MDM2/p53 interac-
tion (Nutlin-3a) leads to the reactivation of p53 functions and rapid
apoptosis in neuroblastoma and other cancer cells [5,6]. Further-
more, MYCN-driven transactivation of MDM2 seems to inhibit
apoptotic responses in neuroblastoma cell lines and primary cultures
[30], but this has not been tested in vivo. Based on the central role of
MYC oncogenes in neuroblastoma tumorigenesis and the necessity of
inhibiting wild-type p53 activity to prevent apoptosis, we hypothe-
sized that MDM2-mediated suppression of p53 is a vital component
of MYCN-driven tumor initiation and progression.
The tumor suppressor ARF, produced as an alternative reading
frame of the p16INK4a gene, is the second most commonly mutated
tumor suppressor in human malignancies behind p53 [31–34]. In
contrast to p53, which responds to a variety of stresses, ARF is pri-
marily activated by oncogenic stress and acts to counteract the pro-
liferative activity of oncogenes such as MYC. ARF is frequently
inactivated by gene deletion or promoter methylation [35,36]. This
leads to less ARF/MDM2 complexes and more MDM2 free to in-
hibit p53. In normal cells, p53 downregulates ARF gene expression,
forming an autoregulatory feedback loop [37].
To test this hypothesis, we crossed the well-characterized pTH-
MYCN transgenic model of neuroblastoma and the Mdm2 haplo-
insufficient mouse model [38] and compared tumor latency and
incidence in the resulting animals. We found that Mdm2+/−MYCN+/+
transgenics had markedly delayed tumor development and had a lower
overall incidence of tumors, strongly implicating Mdm2-mediated
blockade of p53 as an essential step in the pathogenesis of neuroblas-
toma. Analysis of the resulting tumors demonstrated high levels of
p53 and dramatically decreased levels of Arf. We further confirmed
the impact of MDM2 levels on neuroblastoma growth in xenograft
models using conditional short hairpin RNA (shRNA)–mediated
knockdown of MDM2. Based on our data, we propose that both
MYCN-mediated activation of MDM2 and suppression of ARF
contribute directly to the pathogenesis of neuroblastoma. Further
work designing molecular targeted therapies that modulate these
pathways should provide clinically effective novel therapeutic ap-
proaches for neuroblastoma.
Materials and Methods
Cell Lines and Cell Culture
The ZC21 and SJ9 conditional subclones were generated from
human neuroblastoma cells IMR32 (American Type Culture Collec-
tion, Manassas, VA) or SJ3-12 (a gift from Dr. Dirk Geerts, University
of Amsterdam, the Netherlands) by transfection with pSuperior
(OligoEngine, Seattle, WA) plasmids containing 64-bp shRNA hairpin
loop constructs cloned into its unique Bgl II and HindIII sites. The
MDM2messenger RNA (mRNA) sequence targeted with small inter-
fering RNA (siRNA) was gccattgcttttgaagtta. The expression of
shRNA is driven by an inducible (Tet-ON) H1 promoter, which is
activated by the presence of doxycycline. After transfection, cells were
grown under puromycin selection for 2 weeks. Single clones were
isolated, expanded, and characterized for their cellular MDM2 levels
72 hours after doxycycline treatment. Cell lines ZC21 and SJ9, show-
ing remarkably decreased level of MDM2 as determined by Western
blot, were used for the xenograft study. All types of cells were incubated
at 37°C with 5% CO2 in RPMI 1640 medium, supplemented with
10% fetal bovine serum and 1% penicillin-streptomycin (Invitrogen,
Carlsbad, CA) antibiotics.
Western Blot Analysis
Briefly, cell pellets or tissue pieces were lysed in ice-cold cell lysis
buffer (50 mM HEPES, 0.5% NP-40, 250 mM NaCl, pH 7.5) for
20 minutes in the presence of proteinase inhibitor cocktail (Roche,
Indianapolis, IN) and PMSF. Typically, 50 to 75 μg of proteins was
separated by SDS-PAGE on 4% to 15% gradient gels, transferred
to polyvinylidene difluoride membrane, and incubated with indi-
vidual antibodies (p53, p21, and CypB [Santa Cruz Biotechnology,
Santa Cruz, CA]; HDMx/Mdm4 and p14ARF [Bethyl Laboratories,
Montgomery, TX]; MDM2, MYCN, and p19ARF [Calbiochem, San
Diego, CA]; and actin [Sigma, St. Louis, MO]). Immunoblots were
then visualized by using enhanced chemiluminescence kit (GE Health-
care, Piscataway, NJ).
The protein mass of each band in Western blot was quantitatively
measured using Usi-Scan-IT program (Silk Scientific, Inc., Orem, UT).
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The relative amount of protein was calculated, after being divided by the
quantitative mass of loading control proteins (β-actin or cyclophilin B)
on the same lane.
Polymerase Chain Reaction and Reverse
Transcription–Polymerase Chain Reaction
For real-time polymerase chain reaction (PCR), 100 ng of ge-
nomic DNA per reaction was assayed using the SYBR Green PCR
kit (Qiagen, Valencia, CA). Results were normalized to the concen-
tration of β-actin DNA and glyceraldehyde 3-phosphate dehydro-
genase (GAPDH). Conditions for real-time PCR were 95°C for
15 minutes, followed by 45 cycles of 94°C for 15 seconds, 50°C for
30 seconds, and 72°C for 30 seconds. For reverse transcription (RT)–
PCR, 50 ng of cellular total RNA was amplified with RT-PCR kit
(Qiagen). For real-time RT-PCR, 50 ng of total RNA per reaction
was assayed using the SYBR Green RT-PCR kit (Qiagen). Conditions
for real-time RT-PCR were 50°C for 30 minutes, 95°C for 15 minutes,
followed by 45 cycles of 94°C for 15 seconds, 50°C for 30 seconds,
and 72°C for 30 seconds. The relative levels of mRNA and DNA were
calculated by comparing number of cycles at which the PCR products
became detectable above the basal threshold. The sequences of all PCR
primers are listed in Table 1.
Mice Breeding
Mice were handled in accordance with an approved protocol from the
Animal Research Committee of Baylor College of Medicine.Mdm2+/−
mice (C57b strain; Dr. Lozano, MD Anderson Cancer Center) were
first backcrossed for seven generations with wild-type 129/Svj mice to
gainMDM2heterozygousmice with 129/Svj strain (Mdm2+/−MYC−/−).
The neuroblastoma model is highly strain-dependent, and to ensure
equivalent comparisons,Mdm2+/− andMdm2+/+mice were all derived
from the same founding mice and littermates used for all analyses. For
genotyping PCR, tail DNA was prepared using DNeasy kit (Qiagen)
and genotyping for MDM2 performed as previously published [38].
MYCNheterozygosity or homozygosity was confirmed by quantitative
PCR (qPCR) for the human pTH-MYCN transgene using the follow-
ing primers.
Implantation of Neuroblastoma Xenograft
Five million ZC21 or SJ9 cells were resuspended together with
100 μl of Matrigel (BD Biosciences, San Jose, CA) and injected sub-
cutaneously in 4-week-old severe combined immunodeficient (SCID)
mice ( Jackson Laboratory, Bar Harbor, ME) with mixed gender. One
week after injection, mice were separated into two groups that were
fed with drinking water either containing 2 mg/ml of doxycycline or
not. Fresh water with or without doxycycline was served to the mice
once every 2 days until the experiments were complete. The sizes of
tumors in each mouse were measured daily starting from 10 days after
cell injection. The data were plotted using Kaplan-Meier method to
analyze the tumor growth.
Results
Mdm2 Deficiency Extends the Tumor Latency and Decreases
Incidence in MYCN Transgenic Mice
To investigate the role of Mdm2 in neuroblastoma pathogenesis
in vivo, we generated MYCN+/+ transgenic mice (carrying two copies
of the targeted transgene) with either wild-typeMdm2+/+ or a hetero-
zygous knockoutMdm2+/−. The strategy for animal breeding is shown
in Figure 1A. In pTH-MYCN transgenics, the human MYCN gene
is driven by the tyrosine hydroxylase promoter, which is active in
migrating cells of neural crest during early development and in the
resulting peripheral sympathetic nervous tissue from which neu-
roblastoma arises [39]. pTH-MYCN transgenic mouse (MYCN+/+,
129/Svj strain) spontaneously develops neuroblastoma in a MYCN
dose-dependent manner [40,41]. Both cohorts contain two copies
of human MYCN gene, express elevated levels of MYCN in neural
crest precursors and developing sympathetic ganglia [23], and are ex-
pected to develop tumors efficiently, permitting us to study the role
of Mdm2 on MYCN-driven tumors by comparing the two cohorts.
Consistent with previous studies [38,42], we found no difference in
animal weights, activity, oral intake, or fertility between cohorts. As
expected, both Mdm2+/+ and Mdm2+/− mice developed large abdom-
inal neuroblastomas. Tumors from both groups had an aggressive un-
differentiated phenotype with indistinguishable histologic diagnosis,
morphology, and fine structure containing neurosecretory granules
(Figure 1, B and C ; data not shown).
Overall, 110 Mdm2+/− and 117 Mdm2+/+ mice were observed for
up to 1 year. Because no mice died of tumors after 110 days, we
present Kaplan-Meier survival analysis taken out to 200 days (Fig-
ure 3). Mice were monitored at least twice a week for tumor forma-
tion and changes in health status. Mice were killed within 10 days
of the detection of tumors to be examined in accordance with our
institutional review board–approved animal protocol. Figure 2A illus-
trates the statistically significant differences in cumulative survival
probabilities between Mdm2+/− and Mdm2+/+ mice (as analyzed by
Mantel-Cox and Wilcoxon methods). We found a dramatic differ-
ence in the median survival time (defined as time of sacrifice), which
is closely correlated with tumor latency because these tumors, once
fully established, are rapidly fatal. ForMdm2+/+ mice, median latency
was 55 days (95% confidence intervals [CI], 52-57 days), and for
Mdm2+/− mice, tumor latency was 74 days (95% CI, 72-81 days;
P < .001). Thus, the mean time to tumor onset was delayed approx-
imately 20 days (38%) in the Mdm2 haploinsufficient mice, sup-
porting our contention that Mdm2-mediated suppression of p53 is
a rate-limiting step in MYCN-driven neuroblastoma tumorigenesis.
Table 1. Polymerase Chain Reaction Primers Used in This Study.
Target Gene Primers Purposes
Mdm2 ATCTGAGAGCTCGTGCCCTTCG Genotyping
TGTGGCTGGAGCATGGGTATTG
GGCGGAAAGAACCAGCTGGGGC
MYCN TGGAAAGCTTCTTATTGGTAGAAACAA Genotyping
AGGGATCCTTTCCGCCCCGTTCGTTTTAA
MYCN CGACCACAAGGCCCTCAGTA Genomic qPCR
CAGCCTTGGTGTTGGAGGAG
β-actin (mouse) TGCGTCTGGACTTGGCTG Genomic qPCR
TAGCCACGCTCGGTCAGG
p21 (mouse) CCTGACAGATTTCTATCACTCCA qRT-PCR
CAGGCAGCGTATATCAGGAG
Mdm2 CTCTGGACTCGGAAGATTACAGCC qRT-PCR
CCTGTCTGATAGACTGTGACCCG
p19Arf GTCACAGTGAGGCCGCCGCTGA qRT-PCR
TGGGCGTGCTTGAGCTGAAGCTA
p53 (mouse) TCTGGGACAGCCAAGTCTGT qRT-PCR
GGAGTCTTCCAGTGTCATGA
Mdm4 TGAGACCGTGTCAGAGCAATTAGG qRT-PCR
TCCACGTCAGTATCATCGCTCAAG
Gapdh TCACCACCATGGAGAAGGC qRT-PCR
GCTAAGCAGTTGGTGGTGC
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Overall, the MYCN transgenic mice wild type for Mdm2 had a
very high incidence of tumors with 94% (110/117) of mice develop-
ing tumors, in line with previously published studies of the pTH-
MYCN tumor model in the Svj-129 background [23,24]. However,
the Mdm2 haploinsufficient mice had a significantly lower incidence
of 80% overall (88/110 total; P < .001). This difference was sex-
dependent (Figure 2, B and C). Seventy-six percent of female Mdm2+/−
mice (47/62 animals) developed tumors compared with 93% (55/
58 animals) of femaleMdm2wild-type mice (P < .001). For male mice,
Mdm2 haploinsufficiency had an insignificant influence on overall
tumor incidence, with 89% (43/48 animals) of the Mdm2+/− mice
compared with 95% (55/59 animals) of the Mdm2 wild-type mice
developing tumors (P value not significant; Figure 2B). Further anal-
ysis of tumor latency according to sex revealed a trend toward in-
creased latency in the male Mdm2+/− mice compared with the female
Mdm2+/−, but this was not significant by Cox regression analysis (Fig-
ure 2, legend ). No sex-dependent difference in latency or incidence was
seen in theMdm2 wild-type pTH-MYCNmice (data not shown). The
significant decrease in tumorigenesis in the female Mdm2-deficient
mice may be secondary to interaction between MDM2 and the
estrogen-dependent signaling in these mice (Discussion).
Because a major role of MDM2 is inhibition of p53 activity, it is
possible that the delay to tumor formation and the reduced incidence
reflect the need for additional genetic events to overcome increased
p53-mediated tumor suppression. Mutations or deletion of the p53
gene is exceptionally rare in primary human neuroblastoma, although
there is an increased frequency of p53 mutations in relapsed tumors
[7,43]. Because decreased Mdm2 and increased baseline p53 levels
could lead to selective pressure to mutate p53 during tumorigenesis,
we analyzed the sequences of p53 complementary DNA in a repre-
sentative sample of tumors. Sequence data from 15 Mdm2+/− and
8 Mdm2+/+ tumors revealed only wild-type p53 (data not shown),
consistent with the almost complete absence of p53 mutations found
in primary human neuroblastomas [8].
Mdm2 Deficiency Alters p53 Regulation and Activity
in Neuroblastoma
The data shown in the previous section suggest that Mdm2 is crit-
ical for the development of MYCN-driven tumors and that a 50%
decrease in Mdm2 significantly alters tumorigenesis. In cultured
neuroblastoma cells, siRNA-mediated knockdown of MDM2 leads
to a significant increase of p53 and sensitization to apoptotic stress
[30]. To better understand the regulation of p53 and related proteins
in Mdm2+/− and Mdm2+/+ tumors, we performed semiquantitative
Western blot and qRT-PCR analysis of Mdm2, p53, p21, Mdm4,
p19Arf, and MYCN in 12 tumors from each cohort, as shown in Fig-
ure 3, A–C . As expected, Mdm2 mRNA and protein levels are
reduced to approximately 50% of wild type in the Mdm2 haploin-
sufficient mice. Western blots demonstrate that p53 protein levels are
remarkably higher in Mdm2+/− tumors, whereas the mRNA levels do
not differ. This is consistent with decreased Mdm2-mediated ubiqui-
tination of p53 and relative stabilization of the protein compared
with Mdm2+/+ tumors.
A primary transcriptional target of p53 is p21CIP1/WAF1, which en-
codes the cyclin-dependent kinase inhibitor, p21, a central cell cycle
regulator. Consistent with observations of increased p53 protein and
Figure 1. Generation of compound transgenic animals. (A) Breeding scheme used to generate matched sibling cohorts of Mdm2 haploin-
sufficient and Mdm2 wild-type mice with the homozygous human MYCN transgene in Svj-129 mice. The haploinsufficient mice were ob-
tained from Dr. Lozano (MD Anderson Cancer Center) and backcrossed a minimum of seven generations into Svj-129 mice and then bred
into the pTH-MYCN transgenic strain to obtain bothMdm2+/− andMdm2+/+/MYCN+/+ compound transgenic mice. (B) Hematoxylin/eosin
staining of bothMdm2+/− andMdm2+/+ tumors shows an aggressive undifferentiated histologic finding. (C) Tumors in bothMdm2+/− and
Mdm2+/+ were highly proliferative, and no differences in Ki-67 staining could be detected.
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presumably its transcriptional activities, the average p21 mRNA
in Mdm2+/− tumors was approximately 80% higher than that in
Mdm2+/+. However, a trend toward decreased p21 protein levels is
observed in Mdm2+/− tumors, suggesting that p21 protein is destabi-
lized in these tumors. Interestingly, it has been shown that Mdm2 can
inhibit p21 by promoting its ubiquitin-dependent and -independent
proteosomal degradation [44,45]. However, decreased p21 protein
levels would not be expected to correlate with decreased Mdm2 levels
in Mdm2+/− mice, and an alternative mechanism for p21 protein re-
duction is likely invoked in this cohort.
We also analyzed levels of Mdm4 (also termed MdmX), a homolog
of Mdm2 with overlapping and distinct regulatory effects on p53
[46]. The binding of Mdm4 to p53 at its N-terminal transactivation
domain suppresses its transactivation activity [47], and Mdm4 has
potent cell cycle effects independent of Mdm2 [48]. Although a
trend toward decreased levels of Mdm4 can be seen, no significant
change in Mdm4 protein or mRNA levels were detected. This sug-
gests that Mdm4 levels do not compensate for low Mdm2 levels in
Mdm2+/− tumors.
p19Arf Is Transcriptionally Repressed in Mdm2
Haploinsufficient Tumors
The p19 Arf protein product Arf binds to and inactivates Mdm2
leading to the stabilization of p53 and subsequent apoptosis. Arf
has both p53-dependent and p53-independent functions [31], and
it has been shown to specifically bind to both human and mouse
MYCC [49] and MYCN [50], inhibiting Myc transcriptional activity
Figure 2. Tumor development in Mdm2+/− and Mdm2+/+ pTH-MYCN transgenic mice. Kaplan-Meier survival probability curves plotted
for Mdm2+/+/MYCN (solid line) and Mdm2+/−/MYCN (dashed line) transgenics at 200 days of observation. (A) Combined analysis of
110 Mdm2+/− and 117 Mdm2+/+ mice shows a marked increase in median time to death (latency) and an overall decrease in tumor
incidence (P < .001) consistent with the hypothesis that Mdm2 contributes directly to tumorigenesis in this model. (B) When analyzed
according to sex, no difference in incidence was observed, but a significant increase in latency can be seen (P< .001). (C) For the female
mice, an increase in latency but a pronounced decrease in incidence is now seen. No sex-dependent difference in tumor development
was observed in the Mdm2+/+ mice (latency 55 days [95% CI, 52-57 days]). Latency was 80 days (95% CI, 65-95 days) for the male
Mdm2+/− mice and 71 days (95% CI, 63-78 days) for the female Mdm2+/− mice. Statistical analysis was performed with the SPSS
software version (Gradware, Inc., Austin, TX), and both log-rank (Mantel-Cox) and Wilcoxon methods were applied. Comparisons of survival
and latency between sexes for each genotype were performed by Cox regression analysis. Mouse totals: Mdmd2+/−, 62 females and
48 males; Mdm2+/+, 58 females and 59 males.
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and opposing the proliferative signals from oncogenes [51]. We
therefore sought to determine Arf expression in both cohorts of mice.
Initially, we observed a striking lack of Arf expression at the pro-
tein level in most Mdm2+/− tumors and high expression in most
Mdm2+/+ tumors (Figure 3B), consistent with their corresponding
levels of Arf mRNA (Figure 3A). The p19 Arf locus was not deleted
as confirmed by quantitative genomic PCR (data not shown), sug-
gesting an epigenetic mechanism for decreased Arf expression in
the Mdm2+/− tumors. To test it, we isolated primary tumor cell lines
from a Mdm2+/− tumor with no detectable Arf expression and a
Mdm2+/+ tumor with average expression. These transgenic mouse tu-
mor lines were isolated by passaging tumors directly in mice and then
in cell culture. We treated both lines with 1 μM of the demethylating
agent 5′-aza-cytidine (aza-C) and the nonspecific histone deacetylase
inhibitor trichostatin A. As shown in Figure 3, D and E , re-expression
of Arf could be detected within 48 hours of treatment with either
agent by both qRT-PCR and Western blot analysis.
As presented in Table 2, lack of Arf expression was commonly
present in Mdm2 haploinsufficient Mdm2+/− tumors, but it was un-
commonly observed in the Mdm2 wild-type Mdm2+/+ tumors. In
Mdm2+/− tumors, we have noted a statistically significant correla-
tion with the level of Arf expression and the time to tumor develop-
ment (Table 2), suggesting a key role of Arf on suppressing tumor
growth when p53 levels are high. The exact role of Arf on inhibiting
tumor growth is unclear; however, the increased tumor latency in
Mdm2+/− may be due to the increased time required to silence the
p19 Arf locus through DNA methylation or histone deacetylation
events (Discussion). This protective effect of Arf is consistent with
further decreased Mdm2 activity and increased p53 function in
Mdm2+/− tumors.
Figure 3. Gene expression patterns in tumors of Mdm2+/− and Mdm2+/+ mice. (A) Comparison of relative transcript levels of Mdm2,
p53, Arf, p21, and Mdm4 genes. (B) Comparison of relative protein levels of MYCN, Mdm2, p53, p19Arf, p21, and Mdm4. (C) Repre-
sentative Western blot of MYCN, Mdm2, p53, p19Arf, p21, and Mdm4. Analysis of protein levels in whole-cell extracts of tumors was
assayed by immunoblot analysis using antibodies specific to each protein. Lanes 1 to 4 are for Mdm2+/−, whereas lanes 5 to 8 are
for Mdm2+/+. Immunoblot analysis was also carried out for either β-actin or cyclophilin B as loading control. (D and E) There is re-
expression of Arf gene in Mdm2+/− tumor cells after treatment with aza-C or trichostatin A (TSA), as shown by the increase of Arf
transcript (D) and Arf protein (E). Student’s t test was used for statistical analysis to evaluate significance.
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MDM2 Knockdown Suppresses Growth of Neuroblastoma
Xenograft Formation
To further investigate the effect of MDM2 levels on human neu-
roblastoma growth in vivo, we used a xenograft model in SCID mice.
We generated two human neuroblastoma cell lines, ZC21 and SJ9,
expressing tet-inducible shRNA-targeting MDM2, constructed using
IMR32 and SJ3-12 cells, respectively. IMR32 cells harbor wild-type
p53, whereas SJ3-12 cells have a homozygous p53 deletion removing
a 21–amino acid region of the DNA binding domain of p53 leading
to the loss of transactivation activity. In ZC21 cells, MDM2 mRNA
dropped to approximately 5% of the control level in 24 hours after
doxycycline addition (data not shown), whereas the MDM2 protein
decreased to approximately 50% and 10% in 48 and 72 hours, re-
spectively (Figure 4A). Decrease of the MDM2 level was also ob-
served in SJ9 cells (Figure 4B).
Fifteen age-matched SCID mice received subcutaneous injection
with ZC21 cells, and tumor sizes were then monitored every 3 days.
Eight test mice were given water containing 2 mg/ml doxycycline,
whereas seven control mice were given plain water. As expected,
the MDM2 level in the tumors from doxycycline-treated mice was
substantially reduced compared with that from the untreated mice
(Figure 4C ). Tumor growth in these mice was individually tracked
by serial measurements, and at 5 weeks, mice were killed, tumors
were resected, and their sizes were measured. As shown in Figure 4G ,
mice treated with doxycycline developed smaller tumors than mice
given with water only. In mice without doxycycline, the average tu-
mor size was 1.1 cm3, whereas mice treated with doxycycline devel-
oped tumors, with an average of 0.4 cm3 (P < .001), indicating that
the tumor growth was remarkably suppressed by MDM2 depletion.
As anticipated, MDM2 knockdown led to markedly elevated levels
of p53 in the xenograft tumors (P < .001; Figure 4E ), suggesting that
a p53-dependent mechanism contributes to tumor growth suppres-
sion in this model. Interestingly, we saw a decrease in ARF protein
levels in the MDM2 knockdown xenografts (P < .005), reflecting
what was seen in the transgenic mouse model (Figure 4E ). This
may be due to the increased p53-dependent suppression of ARF
[32]. To determine whether inhibition of xenograft growth was
p53-dependent, we grew xenografts with the p53-mutant SJ9 con-
ditional cell line that contains a 22–amino acid deletion within the
p53 DNA binding domain (Figure 4D). In this line, MDM2 level
was decreased by doxycycline treatment, whereas both p53 and
ARF levels did not change (Figure 4F ). Lack of p53 stabilization
in response to Mdm2 silencing may be secondary to altered p53 turn-
over or ubiquitin-independent mechanisms of p53 regulation in this
cell line. We saw no significant tumor suppression on MDM2 knock-
down in the p53 mutant SJ9 line, which suggests that growth inhibition
seen in the ZC21 cell line on MDM2 knockdown is p53-dependent.
Taken together, these data demonstrate strong MDM2-dependent ef-
fects downstream of MYCN transactivation in both transgenic mouse
tumors and human MYCN-amplified xenografts.
Discussion
In the data presented in this study, we provide the first in vivo
evidence that MDM2 contributes to MYCN-driven tumorigenesis
in neural crest–derived neuroblastoma with both Mdm2 haploin-
sufficient transgenic mice and human neuroblastoma xenografts in
SCID mice using cell lines with shRNA-mediated conditional knock-
down of MDM2. Both tumor latency and tumor incidence are signif-
icantly altered by the reduction in Mdm2 levels in the transgenic
model. Importantly, tumor latency was also correlated with Arf levels
in the p53 wild-type tumors. Molecular analyses comparing tumors
from Mdm2+/− and Mdm2+/+ reveal down-regulation of p19Arf expres-
sion at both the mRNA and protein level without gene deletion. Treat-
ment of haploinsufficient tumor cells with the demethylating agent
aza-C leads to rapid up-regulation of both p19Arf message and protein
levels and stabilization of p53. In the next paragraphs, we discuss the
potential function of Mdm2 as an effector of Myc-driven tumorigen-
esis in neuroblastoma through the disruption of the Arf/Mdm2/p53
regulatory network and p53-mediated tumor suppression. These re-
sults are placed in context of neuroblastic tumor initiation and progres-
sion in the pTH-MYCN transgenic mouse model of neuroblastoma.
We found a high rate of p19 Arf suppression in Mdm2+/− tumors
that are driven by MYCN and develop in the context of Mdm2 hap-
loinsufficiency. Such suppression seems to be due to epigenetic si-
lencing because the expression of p19 Arf gene can be reactivated in
culture tumor cells by epigenetic treatment. However, we have not
identified the specific mechanism as to how p19 Arf is regulated or
identified at what point during tumorigenesis this event occurs. Nev-
ertheless, our data support the hypothesis that reduction of ARF level
is an important step for the development of p53 wild type MYCN-
driven neuroblastoma in MDM2-deficient mice and in human tu-
mor cell lines.
We also demonstrate a strong influence of sex on tumor incidence
in the Mdm2 haploinsufficient mice with overall tumor rate, decreas-
ing more than 18% in the female Mdm2+/− mice (P < .001). The
Table 2. Relationship between p53 and p19Arf Levels with the Life Span of Mice from Cohorts A
and B.
Mouse p53 (%) p19Arf (%) Life Span (Days)
Mdm2+/−
A1 372 57 122
A2 198 104 96
A3 215 55 95
A4 593 82 92
A5 160 9 80
A6 569 3 79
A7 223 3 68
A8 264 12 63
A9 487 5 61
A10 275 11 60
A11 103 19 59
A12 305 13 45
Mdm2+/+
B1 79 138 80
B2 83 148 74
B3 120 36 71
B4 88 140 57
B5 110 56 56
B6 75 100 55
B7 161 193 54
B8 73 47 52
B9 124 59 51
B10 123 143 49
B11 104 28 48
B12 66 113 44
We determined the relative p53 and p19Arf protein levels in individual tumors by comparing the
normalized values determined by Western blot analysis (with β-actin and cyclophilin B as loading
controls) to the average level of each protein for all the Mdm2 wild-type tumors, which was ar-
bitrarily defined as 100%. As shown, most Mdm2+/− tumors had markedly lower levels of p19Arf
and markedly higher levels of p53 compared with the Mdm2+/+ tumors. Signal levels were deter-
mined as described in the Materials and Methods section.
A clearly prolonged survival was noted in the tumors with relatively high p19Arf levels (shown in
bold). This correlation was statistically validated using Cox regression analysis of time to sacrifice
versus Arf level, which showed a correlation of R = 0.07 (P < .012) in the Mdm2+/− animals. No
such correlation was evident in the Mdm2 wild-type tumors (R = 0.18, P = .57).
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estrogen receptor α (ERα) interacts with Mdm2 and p53 and can
inhibit Mdm2-mediated ubiquitination of p53 [52]. Subsequent
increased p53 activity may be sufficient to further suppress tumori-
genesis in female Mdm2 haploinsufficient mice. However, ERα may
also act to increase Mdm2 levels indirectly and alter glucocorticoid
receptor signaling [53], and Mdm2 can enhance ERα activity in
breast cancer cells [54]. It is also possible that p53-independent
functions of Mdm2 or mouse strain–specific effects account for the
observed inhibition of tumorigenesis in the female mice. Neuro-
blastoma is almost exclusively found in premenarchal children, and
clinical and mechanistic implications of these findings will require
additional investigation.
Although the interactions of MDM2 and ARF have been well de-
tailed [32], the observation of a direct interaction between MYCN
and ARF adds an additional level of complexity to MYCN-driven
tumorigenesis. Recently, it was shown that ARF can inhibit MYCN-
mediated transcription through binding to both the MYCN DNA
binding domain and its transactivation domains [50]. In our trans-
genic mice with only one functional Mdm2 allele, it seems that low
Mdm2 levels increase selective pressure to silence Arf during the pro-
cess of malignant transformation/progression. There is little Arf sup-
pression in the wild-type tumors. These results suggest that with
normal (or high) Mdm2 levels, MYCN-driven transcription can over-
come ARF-mediated suppression of MDM2, sufficiently repressing
p53 for tumorigenesis to proceed. This model agrees with clinical data
showing very rare epigenetic silencing or deletion of ARF in human
neuroblastoma tumors [10,55] and also agrees with our data showing
increased latency of the haploinsufficient Mdm2+/− tumors because
more time and cell divisions may be needed for Arf suppression to
occur in vivo (Figure 2).
Figure 4. Xenograft tumor models of human neuroblastoma cell lines ZC21 and SJ9. (A and B) Change of MDM2 protein level after
induction of shRNA-targeting MDM2 gene in ZC21 (A) and SJ9 cells (B), respectively. As shown, MDM2 level is remarkably decreased
48 to 72 hours after induction of MDM2-specific shRNA with doxycycline. (C) Growth of xenograft tumors with the injection of ZC21
cells. After injection, mice were given water with or without 2 mg/ml doxycycline. The growth of xenograft tumor was significantly
reduced by doxycycline feeding (solid line) compared with the tumor growth without doxycycline (dashed line). (D) Growth of tumor
growth for SJ9. As shown, the growth of xenograft tumor with doxycycline feeding is slightly but nonsignificantly slower than con-
trol tumors. (E and F) Representative immunoblot for protein levels of MDM2, p53, and p19ARF from three xenograft tumors injected
with ZC21 (E) or SJ9 cells (F), respectively. (G) Sizes of individual xenograft tumors injected with ZC21 cells. Student’s t test was used for
statistical analysis.
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Both MYCN and MYCC activate apoptosis and stimulate prolif-
eration simultaneously in culture cells. How the neural crest–derived
precursors of neuroblastoma respond to aberrant MYC activation
clearly depends on direct MYC transcriptional targets and on indirect
and parallel oncogenic stimuli. Recent studies comparing the sympa-
thetic ganglia of pTH-MYCN and wild-type mice have shown that
MYCN expression leads to the persistence of proliferative rests of
neuroblasts and that this correlates with tumorigenesis in a MYCN
gene dose-responsive manner [41]. The aberrant expression of MYCN
(normally shut down early in embryogenesis) likely disrupts apopto-
sis and differentiation favoring the proliferation of these “neuroblast”
cells. We demonstrate that haploinsufficiency of Mdm2 clearly pro-
longs tumor latency and decreases the incidence of tumor develop-
ment in this same pTH-MYCN model. Lower levels of Mdm2 may
weaken the oncogenic effect of MYCN in neuroblast precursors, in-
creasing the requirement for additional genetic changes such as epi-
genetic silencing of ARF.
Similar findings to our data have been demonstrated in a different
MYCC (C-Myc)-driven lymphoma model. In Eμ-Myc transgenic,
overexpression of MYCC in B cells leads to B-cell lymphoma devel-
opment, accompanied with frequent inactivation of p53 or ARF [56].
In this transgenic model, loss of one Mdm2 allele increased p53-
dependent B-cell apoptosis and reduced lymphomagenesis [57,58].
Suppression of Eμ-Myc lymphoma by Mdm2 deficiency was rescued
by the inactivation of p53 or ARF [57,58], and lymphogenesis was
accelerated by the overexpression of Mdm2 [59]. Whereas MYCN
and MYCC have distinct expression profiles and transcriptional tar-
gets, our data in neuroblastoma (a neuronal crest–derived solid tumor)
suggest a common requirement for p53 suppression downstream of
C-Myc or MYCN oncogenes.
The clinical implications of these data are as follows. First, they
strongly concur with two recent genetic analyses of neuroblastoma
patient samples, suggesting that an activating single nucleotide poly-
morphism (SNP) in the human MDM2 promoter, SNP(309T to G),
correlates with a shorter time to relapse and a shorter time to death
[60,61]. The SNP309 modifies an SP1 transcription factor binding
site in the MDM2 promoter, increasing affinity for SP1 and sub-
sequent MDM2 transcription and attenuated p53 responses [62].
Thus, elevated MDM2 transcription seems to significantly alter the
behavior of human neuroblastomas. Importantly, the incidence of
homozygosity for the activating SNP (i.e., G/G allele) in neuroblas-
toma patients is twice that of controls [61], suggesting that elevated
MDM2 levels contribute to neuroblastoma tumorigenesis. Second,
after the induction of chemotherapy in the context of minimal re-
sidual disease, suppression of MDM2 activity with small-molecule
inhibitors may prevent tumor regrowth and relapse, which is the pri-
mary cause of death in neuroblastoma. Previous in vitro studies dem-
onstrate that neuroblastoma cells are extremely sensitive to MDM2
inhibitors, such as Nutlin-3a [5,6], which activate p53-directed apop-
tosis. This work lends further support to the therapeutic approach of
using small-molecule inhibitors of MDM2 to “de-repress” p53 in
several phases of treatment.
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